pdufa.bio
HomeDecisions › ARQT 2026-06-30

ARQT FDA decision — Jun 30, 2026

✓ APPROVED

Arcutis Biotherapeutics Inc. — ZORYVE (roflumilast) Cream 0.3% · Plaque Psoriasis in Children Ages 2 to 5.

Run-up into the decision (T-120 → T+5)

PDUFA 6/30/26$29.88$19.51/13/26
Daily close, T-120 (1/13/26) through T+5. Run-up high $29.88 on 1/15/26, low $19.5 on 5/21/26 (T-120 to T-1). FDA decision 6/30/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-30
OutcomeApproved
Drug / candidateZORYVE (roflumilast) Cream 0.3%
CompanyArcutis Biotherapeutics Inc.
120-day run-up (T-120→T-1)-8.4%